Kidney Transplantation

Our Program

Program Highlights

  • Program inception: 1966
  • More than 180 adult kidney transplants performed each year
  • National leader in solid-organ and living-donor kidney transplantation
  • Expertise in minimally invasive living-donor surgery

Kidney Transplantation at UPMC

As part of UPMC’s Thomas E. Starzl Transplantation Institute, the Kidney and Pancreas Transplantation Program offers transplantations of a kidney, pancreas, or both organs to patients who suffer from acute or end-stage kidney disease, or complications of diabetes.  The program offers traditional transplantation of these organs from deceased donors as well as living-donor kidney transplantation options.

Our experts have pioneered immunosuppression regimens and introduced a preconditioning treatment and a mostly steroid-free protocol with consistently favorable results for transplant patients. This protocol reduces multiple-drug, heavy-maintenance immunosuppressive therapy and drug toxicity. 

Because of our role as a leader in the field of solid organ transplantation, our program is consistently challenged with some of the most difficult and complex cases. Our kidney, liver, intestinal, and pancreas specialists are experts in their fields. Many are involved in leading research into hereditary aspects of disease, novel therapies, and new ways to use antirejection medicines to improve outcomes for patients.

Volumes and Outcomes

Many factors influence a transplant center’s survival rates, including the patient’s condition. Despite a history of caring for patients with complex medical and surgical problems, we maintain outcomes that are at or near national benchmarks. To view specific information about our outcomes, including one- and three-year survival rates, please visit the Scientific Registry of Transplant Recipients.

Research in Abdominal Transplantation

UPMC is a leader in immunosuppressive therapy and other cutting-edge research and advancements. Our latest work focuses on reducing or even, in a few cases, eliminating the need for antirejection medication to support long-term outcomes. This includes pioneering recipient pretreatment (preconditioning) to prevent initial rejection, while reducing the need for high doses of antirejection medications with long-term follow-up.